Clinical Trial: Expanded Access Program for Magrolimab
Study Type: Expanded Access
Brief Summary:
The primary objective of this study is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory higher-risk myelodysplastic syndrome (MDS) or relapsed or refractory acute myeloid leukemia (AML).
Read more